Anxo Vilarino-Rio
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Metabolic regulation of histone acetylation by ACLY supports MDR1 expression in colorectal cancer and highlights a targetable vulnerability.
Journal: Neoplasia (New York, N.Y.)
Published: April 01, 2026
Aurora kinase A drives non-canonical YAP1/TAZ crosstalk to sustain primary resistance to anti-EGFR therapies in colorectal cancer.
Journal: Molecular therapy. Oncology
Published: February 15, 2025
Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer.
Journal: British journal of cancer
Published: May 27, 2024
Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Journal: British journal of cancer
Published: April 04, 2024
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Journal: British journal of cancer
Published: October 16, 2023
Vitamin-C-dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest.
Journal: Molecular oncology
Published: July 31, 2023
Galectin-1, a novel promising target for outcome prediction and treatment in SCLC.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: August 02, 2022
Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 23, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026